N-[4-[6-(2-methylimidazol-1-yl)pyridazin-3-yl]oxyphenyl]-2,3-dihydro-1-benzofuran-5-sulfonamide
C22H19N5O4S — CID 122306812
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[4-[6-(2-methylimidazol-1-yl)pyridazin-3-yl]oxyphenyl]-2,3-dihydro-1-benzofuran-5-sulfonamide
N-[4-[6-(2-methylimidazol-1-yl)pyridazin-3-yl]oxyphenyl]-2,3-dihydro-1-benzofuran-5-sulfonamide (PubChem CID 122306812) has the molecular formula C22H19N5O4S and a molecular weight of 449.49 g/mol. Its IUPAC name is N-[4-[6-(2-methylimidazol-1-yl)pyridazin-3-yl]oxyphenyl]-2,3-dihydro-1-benzofuran-5-sulfonamide.
Molecular Properties
| Compound Name | N-[4-[6-(2-methylimidazol-1-yl)pyridazin-3-yl]oxyphenyl]-2,3-dihydro-1-benzofuran-5-sulfonamide |
|---|---|
| PubChem CID | 122306812 |
| Molecular Formula | C22H19N5O4S |
| Molecular Weight | 449.49 g/mol |
| Exact Mass | 449.12 |
| IUPAC Name | N-[4-[6-(2-methylimidazol-1-yl)pyridazin-3-yl]oxyphenyl]-2,3-dihydro-1-benzofuran-5-sulfonamide |
| SMILES | Cc1nccn1-c1ccc(Oc2ccc(NS(=O)(=O)c3ccc4c(c3)CCO4)cc2)nn1 |
| InChI | InChI=1S/C22H19N5O4S/c1-15-23-11-12-27(15)21-8-9-22(25-24-21)31-18-4-2-17(3-5-18)26-32(28,29)19-6-7-20-16(14-19)10-13-30-20/h2-9,11-12,14,26H,10,13H2,1H3 |
| InChIKey | QHPODRQEQBUDPE-UHFFFAOYSA-N |
| XLogP | 3.50 |
| TPSA | 108.23 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 449.49 |
| LogP ≤ 5 | 3.50 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 122306812 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.